Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875435 | 1.00 | SLC6A4 (0.58) | SLC6A4TP53TSHRTAAR1SLC6A2 | |
| SCHEMBL9292319 | 1.00 | SLC6A4 (0.58) | SLC6A4TP53TSHRTAAR1SLC6A2 | |
| SCHEMBL10872752 | 0.83 | TAAR1 (0.76) | SLC6A4TAAR1SLC6A2SLC6A3MAOA | |
| SCHEMBL17504541 | 0.83 | TP53 (0.55) | SLC6A4TP53TSHRTAAR1SIGMAR1 | |
| SCHEMBL8671989 | 0.83 | SLC6A4 (0.55) | SLC6A4TAAR1SLC6A2SLC6A3MAOA | |
| SCHEMBL10872755 | 0.83 | TAAR1 (0.76) | SLC6A4TAAR1SLC6A2SLC6A3MAOA | |
| SCHEMBL547420 | 0.82 | TSHR (0.62) | TP53TSHRSIGMAR1 | |
| SCHEMBL23986815 | 0.82 | TP53 (0.53) | SLC6A4TP53TSHRSIGMAR1 | |
| SCHEMBL3813110 | 0.81 | HTR2A (0.65) | SLC6A4TAAR1SLC6A2SLC6A3MAOA | |
| SCHEMBL265675 | 0.81 | HTR2A (0.65) | SLC6A4TAAR1SLC6A2SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | SLC6A4 3408/4885TP53 1359/4885TSHR 3534/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | SLC6A4 3371/4885TP53 1430/4885TSHR 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.